<DOC>
	<DOCNO>NCT02405715</DOCNO>
	<brief_summary>This study evaluate addition intranasal oxytocin treatment Major Depression use interpersonal psychotherapy . Half participant receive placebo adjunct interpersonal psychotherapy , half receive oxytocin .</brief_summary>
	<brief_title>Therapy With Oxytocin Adjunct Major Depression</brief_title>
	<detailed_description>Depression debilitate mental health condition carry great consequence individual society . Crucially , least one third depressed patient respond exist intervention relapse rate high , alert scientist need explore possible adjunctive treatment novel therapeutic target . In regard , research use oxytocin treatment depression promising . It well document interpersonal stress predicts onset depression , social isolation symptom psychological distress leave patient poor prognosis recovery . Therapeutic intervention focus alleviation social conflict strengthen social bond ( i.e . Interpersonal Psychotherapy ; IPT ) show great efficacy treatment depression psychological intervention ( NIMH Treatment Depression Collaborative Research Program ; Elkin et al . 1984 ) . It posit oxytocin , naturally produce hormone involve social-support seek stress-regulation , could represent biological link social stress depression adulthood . The salubrious effect exogenous oxytocin human social behavior well document : Oxytocin show make individual feel securely attach social relationship , increase trust others openness new idea , improve recall specific positive social autobiographical memory , improve social learning . Importantly , factor show improve efficacy Interpersonal Psychotherapy . Thus , It stand reason use oxytocin adjunct IPT could improve efficacy treatment depression , important prospect consider third patient respond exist therapy . In proposed research project , conduct Randomized Controlled Trial treatment Major Depression IPT adjunctive oxytocin . Patients screen eligibility , undergo structure psychotherapy twelve week , follow longitudinally change quality social functioning , interpersonal stress , psychiatric symptom depressive relapse . Establishing novel intervention depression could position healthcare provider well alleviate burden personal suffering cause disorder .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Inclusion Criteria â€¢ Current Major Depressive Episode Exclusion Criteria Visual impairment Major medical illness [ A condition chronic associate impaired functioning , distress , frequent medical intervention ) , particular , subject evidence history malignancy significant hematological , endocrine , cardiovascular ( include rhythm disorder ) , respiratory , renal , hepatic , gastrointestinal disease Acute chronic nasal diseases obstruction Current ( last month ) use endocrinerelevant psychotropic medication prescription antidepressant Current substance dependence abuse Use illicit drug ( stimulant , narcotic , psychedelics/hallucinogens , nonprescription medication ) past 8 week Lifetime history psychosis ( except part MDD ) pervasive developmental disorder Past current comorbid axis1 disorder except Dysthymia , Adjustment Disorder , Generalized Anxiety Disorder , Social Phobia , Specific Phobia . Female Only : Females child bear potential pregnant breastfeed order participate study . They must plan become pregnant , must willing use appropriate contraception throughout study . Female Only : To control hormonal change related pregnancy , female also exclude previously give birth .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>